# Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

> **NCT07357519** · PHASE1,PHASE2 · RECRUITING · sponsor: **Lantheus Medical Imaging** · enrollment: 55 (estimated)

## Conditions studied

- Relapsed / Refractory Osteosarcoma

## Interventions

- **DRUG:** LNTH2403 Phase 1 dose
- **DRUG:** Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).

## Key facts

- **NCT ID:** NCT07357519
- **Lead sponsor:** Lantheus Medical Imaging
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-03
- **Primary completion:** 2027-08
- **Final completion:** 2032-05
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07357519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07357519, "Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07357519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*